{"title":"AP&T: Editors' Declarations of Interest","authors":"","doi":"10.1111/apt.18389","DOIUrl":null,"url":null,"abstract":"<p>\n<i>Professor C. W. Howden, Editor</i>\n</p>\n<p>Professor Howden is a consultant/speaker for Phathom Pharmaceuticals, consultant/speaker for RedHill Biopharma, consultant/speaker for Meridian Diagnostics and consultant for Sebela/Braintree. He owns stock in Antibe Therapeutics and has stock options in EndoStim.</p>\n<p>\n<i>Professor R. Loomba, Editor</i>\n</p>\n<p>Professor Loomba serves as a consultant to Aardvark Therapeutics, Altimmune, Arrowhead Pharmaceuticals, AstraZeneca, Cascade Pharmaceuticals, Eli Lilly, Gilead, Glympse bio, Inipharma, Intercept, Inventiva, Ionis, Janssen Inc. Lipidio, Madrigal, Neurobo, Novo Nordisk, Merck, Pfizer, Sagimet, 89 bio, Takeda, Terns Pharmaceuticals and Viking Therapeutics. He has stock options in Sagimet biosciences. In addition, his institution received research grants from Arrowhead Pharmaceuticals, Astrazeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galectin Therapeutics, Gilead, Intercept, Hanmi, Intercept, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck, Novo Nordisk, Pfizer, Sonic Incytes and Terns Pharmaceuticals. He is also the co-founder of LipoNexus Inc.</p>\n<p>\n<i>Professor A. C. Ford, Associate Editor</i>\n</p>\n<p>Professor Ford has received grant/research support from GE Healthcare and Tillotts Pharma, and acted as a consultant/speaker for Dr. Falk, GE Healthcare, Sandoz and Takeda Pharmaceuticals.</p>\n<p>\n<i>Professor G. M. Dusheiko, Associate Editor</i>\n</p>\n<p>Professor Dusheiko serves on independent data safety monitoring boards for Aligos, Arbutus, Glaxo Smith Kline, Janssen and Gilead. In the past 2 years, he has received honoraria from Arbutus, Antios, Aligos and Gilead Sciences and he serves as an advisor to the National Medical Research Council, Singapore, the TherVacB Consortium (European Horizon Grant) and the A-Tango Consortium (EUH2020 grant).</p>\n<p>\n<i>Professor G. L.-H. Wong, Associate Editor</i>\n</p>\n<p>Professor Wong has served as an advisory committee member for AstraZeneca, Gilead Sciences, GlaxoSmithKline and Janssen, as a speaker for Abbott, AbbVie, Ascletis Pharmaceuticals, Bristol-Myers Squibb, Echosens, Ferring, Gilead Sciences, GlaxoSmithKline, Janssen and Roche and received research grants from Gilead Sciences.</p>\n<p>\n<i>Professor R. B. Gearry, Associate Editor</i>\n</p>\n<p>Professor Gearry is, or has been, a member of advisory boards for AbbVie, Janssen, Schering-Plough, Zespri, Baxter and Celltrion. He has received honoraria or travel grants from AbbVie, Janssen, Schering Plough, Zespri, Ferring and Celltrion. He has received research grants for investigator-initiated studies from AbbVie, Janssen, Goodman-Fielder, Comvita and Zespri.</p>\n<p>\n<i>Professor C. H. Seow, Associate Editor</i>\n</p>\n<p>Professor Seow is a member of advisory boards for Abbvie, Amgen, Bristol Myers Squibb, Celltrion, Ferring, Fresenius Kabi, Janssen, Lilly, Pfizer, Pharmascience, Sandoz, Sanofi, Shire and Takeda and has been a speaker for Abbvie, Fresenius Kabi, Janssen, Lilly, Ferring, Pfizer, Pharmascience, Shire and Takeda.</p>\n<p>\n<i>Dr S. Subramanian, Associate Editor</i>\n</p>\n<p>Dr. Subramanian is/has been on the speaker bureau for Abbvie, Bristol-Myers Squibb, Celltrion, Dr. Falk Pharmaceuticals, Lilly, Ipsen, Janssen, Eisat and Takeda, and received educational grants from Abbvie, Janssen and Takeda and is/has been an advisory board member for Abbvie, Celltrion, Dr. Falk Pharmaceuticals, Janssen, Takeda and Vifor Pharmaceuticals.</p>\n<p>\n<i>Professor J. A Tye-Din, Associate Editor</i>\n</p>\n<p>Professor Tye-Din has privately, or via his institute, been a consultant or advisory board member for Anatara, Anokion, Barinthus Biotherapeutics, Chugai Pharmaceuticals, Dr. Falk, EVOQ Therapeutics, Equillium, Forte Biosciences, IM Therapeutics, Janssen, Kallyope, Mozart Therapeutics, TEVA and Topas. He has received research funding from Barinthus Biotherapeutics, Chugai Pharmaceuticals, Codexis, DBV Technologies, EVOQ Therapeutics, Immunic, Kallyope, Novoviah Pharmaceuticals, Topas and Tillotts Pharmaceuticals and received Honoraria from Takeda. He is an inventor on patents relating to the use of gluten peptides in coeliac disease diagnosis and treatment.</p>\n<p>\n<i>Dr P. J Trivedi, Associate Editor</i>\n</p>\n<p>Dr. Trivedi receives institutional funding support from the National Institute of Health and Social Care Research (NIHR) Birmingham. He has also received lecture fees from Advanz/Intercept, Albireo/Ipsen, Dr. Falk Pharma, Perspectum Ltd. and Zambon. He has received consulting fees from Advanz/Intercept, Albireo/Ipsen, ChemoMab, Cymabay/Gilead, Dr. Falk, GSK, Kowa, Mirum and Pliant; and grant support from Bristol Myers Squibb, Core (Guts United Kingdom), EASL, Gilead Sciences, GSK, Intercept, Ipsen, LifeArc, Medical Research Foundation (United Kingdom), Mirum, NIHR, PSC Support, Regeneron and The Wellcome Trust.</p>\n<p>\n<i>Dr D. Q. Huang, Associate Editor</i>\n</p>\n<p>Dr. Huang has served as an advisory board member for Gilead and Roche.</p>\n<p>\n<i>Professor R. E. Pounder, Founding Editor 1987–2017; Emeritus Editor and Advisor 2018 to present</i>\n</p>\n<p>None to declare.</p>","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"15 1","pages":""},"PeriodicalIF":6.6000,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alimentary Pharmacology & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/apt.18389","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Professor C. W. Howden, Editor
Professor Howden is a consultant/speaker for Phathom Pharmaceuticals, consultant/speaker for RedHill Biopharma, consultant/speaker for Meridian Diagnostics and consultant for Sebela/Braintree. He owns stock in Antibe Therapeutics and has stock options in EndoStim.
Professor R. Loomba, Editor
Professor Loomba serves as a consultant to Aardvark Therapeutics, Altimmune, Arrowhead Pharmaceuticals, AstraZeneca, Cascade Pharmaceuticals, Eli Lilly, Gilead, Glympse bio, Inipharma, Intercept, Inventiva, Ionis, Janssen Inc. Lipidio, Madrigal, Neurobo, Novo Nordisk, Merck, Pfizer, Sagimet, 89 bio, Takeda, Terns Pharmaceuticals and Viking Therapeutics. He has stock options in Sagimet biosciences. In addition, his institution received research grants from Arrowhead Pharmaceuticals, Astrazeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galectin Therapeutics, Gilead, Intercept, Hanmi, Intercept, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck, Novo Nordisk, Pfizer, Sonic Incytes and Terns Pharmaceuticals. He is also the co-founder of LipoNexus Inc.
Professor A. C. Ford, Associate Editor
Professor Ford has received grant/research support from GE Healthcare and Tillotts Pharma, and acted as a consultant/speaker for Dr. Falk, GE Healthcare, Sandoz and Takeda Pharmaceuticals.
Professor G. M. Dusheiko, Associate Editor
Professor Dusheiko serves on independent data safety monitoring boards for Aligos, Arbutus, Glaxo Smith Kline, Janssen and Gilead. In the past 2 years, he has received honoraria from Arbutus, Antios, Aligos and Gilead Sciences and he serves as an advisor to the National Medical Research Council, Singapore, the TherVacB Consortium (European Horizon Grant) and the A-Tango Consortium (EUH2020 grant).
Professor G. L.-H. Wong, Associate Editor
Professor Wong has served as an advisory committee member for AstraZeneca, Gilead Sciences, GlaxoSmithKline and Janssen, as a speaker for Abbott, AbbVie, Ascletis Pharmaceuticals, Bristol-Myers Squibb, Echosens, Ferring, Gilead Sciences, GlaxoSmithKline, Janssen and Roche and received research grants from Gilead Sciences.
Professor R. B. Gearry, Associate Editor
Professor Gearry is, or has been, a member of advisory boards for AbbVie, Janssen, Schering-Plough, Zespri, Baxter and Celltrion. He has received honoraria or travel grants from AbbVie, Janssen, Schering Plough, Zespri, Ferring and Celltrion. He has received research grants for investigator-initiated studies from AbbVie, Janssen, Goodman-Fielder, Comvita and Zespri.
Professor C. H. Seow, Associate Editor
Professor Seow is a member of advisory boards for Abbvie, Amgen, Bristol Myers Squibb, Celltrion, Ferring, Fresenius Kabi, Janssen, Lilly, Pfizer, Pharmascience, Sandoz, Sanofi, Shire and Takeda and has been a speaker for Abbvie, Fresenius Kabi, Janssen, Lilly, Ferring, Pfizer, Pharmascience, Shire and Takeda.
Dr S. Subramanian, Associate Editor
Dr. Subramanian is/has been on the speaker bureau for Abbvie, Bristol-Myers Squibb, Celltrion, Dr. Falk Pharmaceuticals, Lilly, Ipsen, Janssen, Eisat and Takeda, and received educational grants from Abbvie, Janssen and Takeda and is/has been an advisory board member for Abbvie, Celltrion, Dr. Falk Pharmaceuticals, Janssen, Takeda and Vifor Pharmaceuticals.
Professor J. A Tye-Din, Associate Editor
Professor Tye-Din has privately, or via his institute, been a consultant or advisory board member for Anatara, Anokion, Barinthus Biotherapeutics, Chugai Pharmaceuticals, Dr. Falk, EVOQ Therapeutics, Equillium, Forte Biosciences, IM Therapeutics, Janssen, Kallyope, Mozart Therapeutics, TEVA and Topas. He has received research funding from Barinthus Biotherapeutics, Chugai Pharmaceuticals, Codexis, DBV Technologies, EVOQ Therapeutics, Immunic, Kallyope, Novoviah Pharmaceuticals, Topas and Tillotts Pharmaceuticals and received Honoraria from Takeda. He is an inventor on patents relating to the use of gluten peptides in coeliac disease diagnosis and treatment.
Dr P. J Trivedi, Associate Editor
Dr. Trivedi receives institutional funding support from the National Institute of Health and Social Care Research (NIHR) Birmingham. He has also received lecture fees from Advanz/Intercept, Albireo/Ipsen, Dr. Falk Pharma, Perspectum Ltd. and Zambon. He has received consulting fees from Advanz/Intercept, Albireo/Ipsen, ChemoMab, Cymabay/Gilead, Dr. Falk, GSK, Kowa, Mirum and Pliant; and grant support from Bristol Myers Squibb, Core (Guts United Kingdom), EASL, Gilead Sciences, GSK, Intercept, Ipsen, LifeArc, Medical Research Foundation (United Kingdom), Mirum, NIHR, PSC Support, Regeneron and The Wellcome Trust.
Dr D. Q. Huang, Associate Editor
Dr. Huang has served as an advisory board member for Gilead and Roche.
Professor R. E. Pounder, Founding Editor 1987–2017; Emeritus Editor and Advisor 2018 to present
期刊介绍：
Alimentary Pharmacology & Therapeutics is a global pharmacology journal focused on the impact of drugs on the human gastrointestinal and hepato-biliary systems. It covers a diverse range of topics, often with immediate clinical relevance to its readership.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
